Two recent landmark studies have lent strong support to a health benefit of early initiation of antiretroviral therapy (ART) for asymptomatic human immunodeficiency virus (HIV)-infected patients with high CD4 counts. Both the Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa (TEMPRANO) and the Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection (START) studies reported reductions of over 40% in the risk of death or an acquired immune deficiency syndrome (AIDS)-defining event when ART was initiated immediately instead of waiting until CD4 thresholds were met (\<350 cells/µL in the START study, or the contemporary World Health Organization-based guidelines in the TEMPRANO study) \[[@OFW032C1], [@OFW032C2]\]. Both studies demonstrated decreased risk of opportunistic infections and appreciable, albeit nonsignificant, reductions in all-cause mortality. However, an unexpected result from the START study was the rate of cardiovascular disease (CVD) events, which did not differ between immediate initiators and those deferring therapy (adjusted hazard ratio, 0.84; 95% confidence interval \[CI\], .39--1.81; *P* = .65). The TEMPRANO study, which was not designed to capture cardiovascular events, did not report a similar subanalysis.

The finding that early ART for asymptomatic HIV-infected individuals did not prevent CVD complications seems to contradict a body of evidence relating HIV infection to CVD risk. Most notably, a landmark study comparing CD4-count-guided treatment interruptions with continuous ART (Strategies for Management of Antiretroviral Therapy \[SMART\] study) demonstrated an approximate 70% increase in CVD events in those taking treatment interruptions. Resolving the benefit of ART timing and its impact on CVD risk is a critical question for the field of clinical HIV care. If the benefits are significant, then prioritizing early diagnosis and linkage to ART might provide significant CVD health benefits. If the benefits are not significant, then the search for alternate interventions in addition to ART to mitigate CVD risk in this population will be crucial. This review aims to summarize the evidence about relationships between timing of ART initiation and CVD risk, using nadir CD4 count as a surrogate marker of duration of HIV infection, and with a particular focus on the impact of early ART on prevention of CVD events.

THE SMART STUDY, TREATMENT INTERRUPTIONS, AND CARDIOVASCULAR DISEASE RISK {#s2}
=========================================================================

Soon after it was discovered that combination ART profoundly improved survival for patients with AIDS \[[@OFW032C3], [@OFW032C4]\], it became evident that HIV-infected patients were at higher risk than the general population of non-AIDS-related conditions \[[@OFW032C5]--[@OFW032C8]\]. Cardiovascular disease, and particularly myocardial infarction and stroke, were among the greatest non-AIDS risks, and ART rather than HIV infection was thought to be the primary culprit \[[@OFW032C5], [@OFW032C9], [@OFW032C10]\]. Concerns about avoiding the toxicity of chronic ART in part spurred a change in the US HIV treatment guidelines to downgrade recommendations to initiate ART for those with a CD4 of 200--350 from "recommended" to "optional" during the period 2001--2006 \[[@OFW032C11]\]; and a large randomized controlled trial was conducted to evaluate whether discontinuing ART decreased non-AIDS-related HIV complications. The SMART study randomized approximately 5000 patients infected with HIV on stable ART with a CD4 count above 350 to continuing ART, versus mandated treatment interruptions until CD4 counts dropped below 250, at which point ART was reinitiated \[[@OFW032C12]\].

Arguably the most informative result to come from the SMART study was not that treatment interruptions increased the risk of opportunistic infections or mortality, but that patients taking interruptions from ART had an approximately 70% increased risk of cardiovascular complications; moreover, major cardiovascular events occurred 5 times more often than opportunistic infections in those with treatment interruptions (Table [1](#OFW032TB1){ref-type="table"}). The SMART study suggested that, whereas specific ART drugs or drug classes might be associated with a relative CVD risk versus others \[[@OFW032C13], [@OFW032C14]\], CVD risk is largely mediated by the effects of untreated HIV infection. Table 1.Outcomes Reported in the SMART Study \[[@OFW032C12]\]OutcomeRelative Risk for Treatment InterruptionTotal EventsDeath1.8 (1.2--2.9)85Serious OI6.6 (1.5--29)15Major CV Event**1.7 (1.1--2.5)104**[^1]

Although the primary SMART study analysis did not differentiate between ART interruptions and timing of ART initiation, in a subsequent analysis, the investigators specifically considered a clinical benefit of earlier ART initiation. When limiting their analysis to the 488 study participants who were ART naive or off therapy for a minimum of 6 months before study enrollment, investigators found a 7 times increased hazard of a cardiovascular event or non-AIDS illness in those initiating therapy at \<250 vs \>350 cells/µL \[[@OFW032C15]\]. As the only study randomizing patients to early versus deferred ART initiation with measured CVD outcomes at the time, this study subanalysis offered the strongest clinical evidence for a preventive role for earlier ART initiation.

Since then, an elegant body of basic and translational research has provided a strong pathophysiologic rationale for a causative role for HIV infection on CVD risk \[[@OFW032C16]\]. A combination of immune activation due to HIV and coinfections \[[@OFW032C17]--[@OFW032C19]\], direct HIV infection of vasculature smooth muscle \[[@OFW032C20], [@OFW032C21]\], and profound and irreversible depletion of gut T-lymphocytes with resulting microbial translocation \[[@OFW032C22]--[@OFW032C24]\] are thought to combine to precipitate a chronic inflammatory state. Reactive T-lymphocytes and macrophages \[[@OFW032C25], [@OFW032C26]\] have been correlated with both CVD outcomes and all-cause mortality \[[@OFW032C27]--[@OFW032C30]\]. Indeed, recent data suggest that as mortality for HIV-infected individuals has decreased from AIDS-defining illnesses, CVD has become the second most common cause of death, after cancer, among those with an undetectable viral load \[[@OFW032C31]\]. However, although basic science supports the role of HIV-mediated inflammation as a causative agent in CVD risk, clinical data are crucial to translating this theory into improvements for patient care.

ANTIRETROVIRAL THERAPY TIMING AND PRECLINICAL ATHEROSCLEROSIS {#s3}
=============================================================

A host of nonrandomized studies have investigated the relationship between nadir CD4 count and risk of preclinical atherosclerosis, without convincing evidence for a relationship between disease stage at ART initiation and CVD risk (Table [2](#OFW032TB2){ref-type="table"}). It is notable that although multiple studies have reported a relationship between HIV infection itself and carotid intima media thickness (cIMT) \[[@OFW032C55]\], only 1 has demonstrated an inverse relationship between nadir CD4 count and cIMT (such that a lower nadir CD4 count is associated with a greater mean cIMT) \[[@OFW032C32]\]. In addition, although Hsue et al \[[@OFW032C43]\] reported a relationship between lower CD4 count and cIMT progression over time (Table [2](#OFW032TB2){ref-type="table"}), a large prospective study of over 1000 individuals infected with HIV has since reported a counterintuitive direct relationship (such that higher nadir CD4 count was associated with increased progression) \[[@OFW032C46]\]. These differential estimates might partially be explained by cohort characteristics. For example, patients in the Hsue et al \[[@OFW032C43]\] study had relatively low median nadir CD4 (approximately 200 vs 500 cells/µL), contained a higher proportion of males, and were more likely to be current smokers and have hypertension. Table 2.Summary of Studies Reporting Relationships Between Nadir CD4 Count and Preclinical AtherosclerosisStudyYearStudy DesignHIV-Infected Sample SizeCohort Median Nadir CD4 CountRelationship Between CD4 Nadir and Atherosclerosis RiskMain FindingsCurrent Carotid Intima Media Thickness Jerico et al \[[@OFW032C32]\]2006Cross-Sectional132250InverseIncreased odds of cIMT \>0.8 mm with a nadir CD4 count \<200 vs ≥200 cells/µL (OR, 2.9; 95% CI, 1.4--5.9) Kaplan et al \[[@OFW032C33]\]2008Cross-sectional1931∼450^a^NoneNo association between nadir CD4 count and mean cIMT in men (estimate not reported) Ross et al \[[@OFW032C34]\]2009Cross-sectional73161 (0--868)NoneNo association between nadir CD4 count and cIMT (β \< 0.01, *P* = .88) van Vonderen et al \[[@OFW032C35]\]2009Cross-sectional77∼184^a^NoneNo association between cIMT and nadir CD4 count (estimate not reported) Merlini et al \[[@OFW032C36]\]2012Cross-sectional163210 (99--326)NoneNo difference in nadir CD4 count between those with normal cIMT (≤1 cm), those with increased cIMT (1.0--1.5 cm), and those with carotid plaque (cIMT \> 1.5 cm), (*P* = .74) Longenecker et al \[[@OFW032C37]\]2013Cross-sectional78NRNoneNo association between nadir CD4 count and mean cIMT (*P* = .80) Desvarieux et al \[[@OFW032C38]\]2013Cross-sectional100∼345^a^NoneNo difference in adjusted mean cIMT between ART-naive and on ART (4 y) participants Increase in adjusted mean cIMT between those with HIV more than vs \<8 years (0.760 vs 0.731, *P* = .02) Ssinabulya et al \[[@OFW032C39]\]2014Cross-sectional245124 (42--195)NoneNo difference in nadir CD4 count between those with elevated cIMT (≥0.78) and those with normal cIMT Boyd et al \[[@OFW032C40]\]2014Cross-sectional47∼222^a^NoneNonsignificant association between cIMT and nadir CD4 count (β = −0.001, *P* = .9) Siedner et al \[[@OFW032C41]\]2015Cross-sectional105122 (80--175)DirectIncrease mean cIMT with each increase in nadir CD4 count of 50 cells/µL (0.014 mm, *P* = .02) Pacheco et al \[[@OFW032C42]\]2015Cross-sectional591213 (90--314)NoneMean nadir CD4 count 215 in lowest tertile of cIMT vs 178 in highest tertile of cIMT (*P* = .054)Progression of Carotid Intima Media Thickness Hsue et al \[[@OFW032C43]\]2004Prospective cohort148106InverseIncreased rate of progression of cIMT for participants with a nadir CD4 \< 200 (0.0043 mm/year, *P* = .08) Currier et al \[[@OFW032C44]\]2007Prospective cohort134NR (∼35% with nadir CD4 \< 200)DirectDecreased odds of rapid progression of cIMT (defined as 1 SD, ie, 0.0122 mm/year) for participants with a nadir CD4 count \<200 (AOR, 0.10; *P* = .04) Volpe et al \[[@OFW032C45]\]2013Prospective Cohort345161 (70--276)DirectDecreased rate of cIMT progression for each decrease in 100 cells/µL nadir CD4 count (−0.005 mm/year; SD, 0.002) Hanna et al \[[@OFW032C46]\]2015Prospective Cohort1277∼483^a^NoneNo association between CD4 nadir and progression of cIMT thickness (RR compared \<200 cells vs \>500 cells/µL 1.13, 95% CI, .56--2.29, *P* = .73). Stein \[[@OFW032C47]\]2015Randomized clinical trial328349 (203--455)NoneNo association between pretreatment CD4% and cIMT progression (β = −0.07, *P* = .28)Current Carotid Artery Plaque Kaplan et al \[[@OFW032C33]\]2008Cross-sectional1931∼450^a^InverseIncreased adjusted risk of carotid plaque with lower nadir CD4 count (vs HIV-uninfected as reference group): CD4 nadir \> 500: RR 0.88 (women), 1.24 (men), *P* \> .18CD4 nadir \<200: RR 2.00 (women), 1.74 (men), *P* ≤ .05Incident Carotid Plaque Hanna \[[@OFW032C46]\]2015Prospective Cohort1277∼483^a^InverseIncreased adjusted risk of incident carotid plaque with lower nadir CD4 count (vs HIV-uninfected as reference group): CD4 nadir \>500: RR 1.28, 0.85--1.94, *P* = .23CD4 nadir 350--500: RR 1.65, 1.03--2.64, *P* = .039CD4 nadir 300--350: RR 1.96, 1.20--3.21, *P* = .007CD4 nadir \<200: RR 2.57, 1.48--4.46, *P* \< .001Aortic Wall Inflammation (FDG PET) Subramanian et al \[[@OFW032C48]\]2012Cross-sectional2799 (50--250)NoneNo correlation between nadir CD4 count and aortic wall inflammationPreclinical Coronary Artery Disease Lo et al \[[@OFW032C49]\]2010Cross-sectional78169 (54--263)NoneNo correlation between nadir CD4 count and segment of plaque (*P* = .49), plaque volume (*P* = .66), or Agatston calcium score (*P* = .83) Burdo \[[@OFW032C25]\]2011Cross-sectional102202NoneNo correlation between nadir CD4 count and noncalcified coronary artery plaque (estimate not reported) Duarte et al \[[@OFW032C50]\]2012Cross-sectional26269NoneBorderline, nonsignificant increase in noncalcified plaque volume with decreasing nadir CD4 count (r = −0.36, *P* = .07) Pereyra \[[@OFW032C51]\]2012Cross-sectional113221^a^NoneNonsignificant increased prevalence of plaque on CT coronary angiogram among elite controllers with high nadir CD4 than chronic HIV cohort (78% vs 60%, *P* = .28) Zanni \[[@OFW032C52]\]2013Cross-sectional102175 (57--278)NoneNo correlation between nadir CD4 count and number of low attenuation coronary artery plaques (*P* = .72) Post \[[@OFW032C53]\]2014Cross-sectional618244 (133--332)InverseDecreased risk of coronary artery stenosis \>50% for each 100 cell/µL increase in nadir CD4 count (AOR 0.80, 0.69--0.94, *P* = .005). Abd-Elmoniem \[[@OFW032C54]\]2014Cross-sectional35202NoneNo association between nadir CD4 count and right coronary artery atherosclerosis as measured by CT angiography (no estimate reported)[^2][^3]

Although less commonly evaluated than cIMT, the presence of carotid plaques has been better associated with nadir CD4 count (Table [2](#OFW032TB2){ref-type="table"}). Investigators of the Multi-Centre AIDS Cohort Study and Women\'s Interagency Health Study (MACS/WIHS) have reported greater carotid plaque volume with decreasing nadir CD4 count \[[@OFW032C33], [@OFW032C46]\]. This causal relationship is strengthened by the presence of a dose-response relationship correlating lower nadir CD4 count with increased prevalence and incidence of carotid plaque.

More recently, several studies have reported strong associations between HIV infection and presence of preclinical coronary artery disease and aortic wall inflammation (Table [2](#OFW032TB2){ref-type="table"}). The largest of these, also from the MACS/WIHS collaboration, reported a 20% decreased odds of coronary stenosis (\>50%) for each increase in nadir CD4 count of 100 cells/µL \[[@OFW032C53]\]. However, similar to carotid atherosclerosis, the majority of similar studies have not found significant relationships between nadir CD4 count and preclinical disease (Table [2](#OFW032TB2){ref-type="table"}). It is notable that many of these studies are potentially unpowered to detect associations between nadir CD4 and CVD risk. Nonetheless, a meta-analysis of studies including data from approximately 1000 individuals infected with HIV found no significant association between nadir CD4 count and either noncalcified plaque (*P* = .45) or coronary artery stenosis (*P* = .87) \[[@OFW032C56]\].

ANTIRETROVIRAL THERAPY TIMING AND CARDIOVASCULAR DISEASE OUTCOMES IN COHORT STUDIES {#s4}
===================================================================================

Several large data sets in the United States, including the Veteran\'s Aging Cohort Study (VACS), Partners Healthcare and the Kaiser Permanente Healthcare system, as well as large or national cohorts from France and Denmark, have enabled estimation of HIV-related CVD risk (Table [3](#OFW032TB3){ref-type="table"}). In general, these cohort studies increase the support for associations between nadir CD4 count and CVD risk. For example, in the Kaiser cohort, CVD incidence declined over calendar time (1999--2011) as population nadir CD4 increased. At the conclusion of their observation period (2010--2011), they found no difference in risk of myocardial infarction between HIV-infected and uninfected populations (relative risk \[RR\], 1.0; 95% CI, .7--1.4). The authors \[[@OFW032C67]\] point out that their data might be confounded by the fact that the proportion of patients receiving therapy for CVD-related conditions also increased during the period. However, if their estimates are unbiased, these data would support findings from the START study, which demonstrates normalization of CVD risk, compared with the general population, as nadir CD4 counts increased. A second study from the Kaiser investigators, which included more than 22 000 individuals infected with HIV, specifically assessed relationships between nadir CD4 and CVD risk and demonstrated a decreased risk of myocardial infarction with each 100 cell/µL increase in nadir CD4 count \[[@OFW032C61]\]. A case-control study from France noted a similar relationship \[[@OFW032C59]\]. Moreover, although the Partners cohort investigators, the VACS study investigators, and the HIV Outpatient Study investigators demonstrated relationships between most recent CD4 count and risk of incidence myocardial infarction, they did not assess nadir CD4 count in their reports \[[@OFW032C28], [@OFW032C60]\], or they found no association between nadir CD4 and CVD events \[[@OFW032C58]\]. Finally, of 5 studies that have explored relationships between HIV disease stage and stroke risk, only 1 identified an inverse relationship between CD4 nadir and stroke risk (Table [3](#OFW032TB3){ref-type="table"}), reporting that a nadir CD4 count below 200 cells/µL more than doubled the risk of stroke \[[@OFW032C62]\]. Table 3.Summary of Studies Reporting Relationships Between Nadir CD4 Count and Cardiovascular Disease EventsStudyYearStudy DesignHIV-Infected Sample SizeCohort Median Nadir CD4 CountRelationship Between CD4 Nadir and Atherosclerosis RiskMain FindingsMyocardial Infarction Obel et al \[[@OFW032C57]\]2007Retrospective Cohort3953182 (74--290)None or inverseAbsolute increase in risk of myocardial infarction for those with nadir CD4 count ≤200 cells/µL (RR 2.28, 95% CI, 1.63--3.19) vs those with a nadir CD4 count \>200 cells/µL (RR 1.80, 95% CI, 1.17--2.78). No interaction term reported. Friis-Møller et al \[[@OFW032C5]\]2007Prospective Cohort23 437200 (range 1--2580)NoneNo association between nadir CD4 count and risk of myocardial infarction (0.98, 95% CI, .95--1.01) for each 50 cells/µL increase Lichtenstein et al \[[@OFW032C58]\]2010Retrospective Cohort2005197NoneNo association between nadir CD4 count and subsequent cardiovascular event (OR 1.34, 95% CI, .64--2.83 for nadir CD4 \<350 vs \>500) Lang et al \[[@OFW032C59]\]2012Case Control1173167^a^InverseIncrease in risk of myocardial infarction with each log~2~ decrease in nadir CD4 count (OR 0.90, 95% CI, .83--.97) Freiberg et al \[[@OFW032C60]\]2013Retrospective Cohort27 350362NoneNo association between baseline CD4 (first record in veterans affairs system) and incident myocardial infarction (no estimate reported) Silverberg et al \[[@OFW032C61]\]2015Retrospective Cohort22 081Not reportedInverseDecrease in risk of myocardial infarction with each 100-cell increase in nadir CD4 account (ARR 0.88, 95% CI .81--.96).Stroke Rasmussen et al \[[@OFW032C62]\]2011Retrospective Cohort4495292^a^InverseIncrease in risk of stroke among those not on ART with a nadir CD4 count ≤200 vs \>200 cell/µL (ARR 2.26, 95% CI, 1.05--4.86). Chow et al \[[@OFW032C63]\]2012Retrospective Cohort4308271NoneNo association between nadir CD4 count and risk of stroke (0.97, 95% CI, .90--1.05 for each 50 cells/µL). Vinikoor et al \[[@OFW032C64]\]2013Retrospective Cohort2515235 (69--407)NoneNo association between risk of ischemic stroke and nadir CD4 count ≤200 vs \>200 cells/µL (RR 1.31, 95% CI, .76--2.26) for nadir CD4 count Marcus et al \[[@OFW032C65]\]2014Retrospective Cohort24 768Not reportedNoneAmong the HIV+ group, no association between nadir CD4 count and risk of stroke (RR 0.80, 95% CI, .4--1.6 comparing nadir CD4\<200 with ≥500). Chow et al \[[@OFW032C66]\]2014Case Control6073NoneNo association between nadir CD4 count and odds of ischemic stroke (OR 1.05, 95% CI, .81--1.36 per each 100 cells/µL)[^4][^5]

ANITRETROVIRAL THERAPY TIMING AND CARDIOVASCULAR DISEASE OUTCOMES IN RANDOMIZED CLINICAL TRIALS: SMART VERSUS START {#s5}
===================================================================================================================

Although the above body of evidence suggests a possible, if not inconsistent, role for early ART initiation in mitigating CVD risk, these data have a number of important limitations. First, many of the studies are limited to relatively small sample sizes, preventing the ability to detect small contributions of ART timing to CVD risk. Second, most cohort studies are homogenous in important ways, including restricting to gender (eg, VACS and MACS cohorts), and, more importantly, to small distributions in nadir CD4 count, which limits the ability to compare those initiating early ART with those initiating late ART. Third, and most important, cohort studies are challenged by residual or unmeasured confounding, such that unaccounted factors associated with both nadir CD4 count and CVD risk (eg, access to high-quality primary care services) could alter estimates of the relationship between them. To overcome these limitations, randomization to early or deferred therapy is needed to better estimate relationships between timing of ART and CVD risk.

Both the SMART and START studies addressed this need through randomization of HIV-infected persons to ART or either ART discontinuation (SMART) or deferring ART initiation (START), respectively. As summarized above, the SMART study reported a 70% increased risk of cardiovascular complications for discontinuing therapy, whereas the START study found no increased risk of cardiovascular complications when initiating ART was deferred.

How can we explain the differences between these 2 studies? It is possible that treatment interruptions (as in SMART) have differential effects on CVD risk than delayed therapy among ART-naive individuals (as in START). However, as mentioned above, the SMART investigators identified similar relationships in a substudy limited to those initiating ART \[[@OFW032C15]\]. There are other important differences between the 2 study populations, which theoretically could explain differences in relative rates of CVD events. For example, approximately 50% of patients in the SMART study were on a protease inhibitor, compared with only 20% of patients in the START study, and approximately 6% vs 4% were prescribed abacavir, respectively. Although the regimen imbalance might partially explain the relative increased overall risk of CVD events witnessed in the SMART study, it does not explain the difference in risk comparing those on ART with those who are not. In fact, the relationship observed was counterintuitive, because the regimens in use in the SMART study were more likely to be associated with metabolic abnormalities and would thus be predicted to have a relatively decreased effect on CVD prevention than the regimens used in the START study. Other key differences between study groups include a higher median age in the SMART study (43 vs 36 years) and slightly higher rates of current smoking (40% vs 32%), but it is unlikely that these relatively modest differences would account for the approximately 7-fold increased risk of CVD events noted in the SMART study.

Another key difference between study groups was the nadir CD4 count. At enrollment, study participants in the START study had a median nadir CD4 count of 651 cells/µL and a known HIV duration of only 1 year. Moreover, mean CD4 count in the deferred therapy never dropped below 600 cells/µL. In contrast, the median nadir CD4 in the SMART study was 250 cells/µL, and over half of participants had over 6 years of HIV infection before enrollment. Those in the drug conservation group spent most of the observation time (73%) with detectable viral loads and with CD4 counts \<500 cells/µL. As such, even the deferred therapy group in the START study can be considered to have significantly shorter duration of HIV viremia and duration of time with low CD4 counts compared with those in the SMART continued therapy arm.

An examination of these 2 studies in combination reveals a nonlinear relationship between nadir CD4 count and CVD risk (Table [4](#OFW032TB4){ref-type="table"}), and the results of this review challenges the implication supported by the START study, which, taken in isolation, suggests that early ART does not prevent CVD outcomes. Instead, early and continuous ART for those with advanced disease does appear to be protective against CVD events. However, for those starting ART relatively early (\>500 cells/µL), CVD risk is not clearly reduced substantially by the timing of ART initiation. In other words, above some unclear threshold of immune depletion, earlier ART initiation seems to have a diminished role in preventing CVD risk. It is unlikely that future studies will further elucidate this threshold due to the overwhelming evidence in support of early ART described by the START and TEMPRANO studies. As such, for those starting therapy with preserved immune function, further reductions in risk will likely require additional, non-ART-based interventions. Table 4.Nadir CD4 Count and Cardiovascular Disease Event Incidence in the SMART and START StudiesStudy GroupNadir CD4Cardiovascular EventsEvent Rate(per 1000 person-years) SMART Treatment Interruption Arm∼200651.8 SMART Continued Therapy Arm250391.1 START Deferred Initiation Arm∼600140.20 START Immediate Initiation Arm651120.17[^6]

CONCLUSIONS {#s6}
===========

In summary, the published literature on the timing of ART initiation and CVD risk supports 3 primary conclusions. First, data from the SMART study, in combination with a handful of nonrandomized studies noting relationships between lower nadir CD4 and increased risk of preclinical or clinical CVD \[[@OFW032C32], [@OFW032C43], [@OFW032C53], [@OFW032C59], [@OFW032C61], [@OFW032C62]\], suggest that earlier initiation of ART has a protective effect against CVD events. The majority of these studies, including the SMART study, involved those with relatively low nadir CD4 counts (\<250 cells/µL), which lends the strongest support for the benefit of ART among those with advanced disease. Notwithstanding recent recommendations to initiate ART independent of immune status, this implication remains of importance for much of the world\'s HIV-infected population, because most patients continue to initiate ART well below recommended guidelines \[[@OFW032C68]--[@OFW032C70]\]. Second, a recent group of large cohort studies demonstrate associations between a low recent CD4 count (as opposed to nadir CD4 count) and/or current detectable HIV-1 viremia and clinical outcomes \[[@OFW032C28], [@OFW032C58], [@OFW032C60]\]. In combination with results of the SMART study, these data support a role for continuous ART among those who have initiated therapy, to prevent HIV-associated chronic inflammation and resulting CVD risk. Third, for patients starting ART above a CD4 count threshold of 500 cells/µL, the START study suggests that earlier ART initiation has marginal benefits in terms of mitigating CVD risk. This realization should foster further consideration of non-ART interventions to decrease CVD risk among HIV-infected populations initiating therapy with preserved immune function \[[@OFW032C71], [@OFW032C72]\].
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[^1]: Abbreviations: CV,cardiovascular; OI,opportunistic infection; SMART,Strategies for Management of Antiretroviral Therapy.

[^2]: Abbreviations: AOR, adjusted odds ratio; ART,antiretroviral therapy; CI, confidence interval;cIMT, carotid intima media thickness; CT,computed tomography;FDG-PET, fluorodeoxyglucose-positron emission tomography; HIV, human immunodeficiency virus; NR, not reported; OR, odds ratio; RR, relative risk; SD, standard deviation.

[^3]: ^a^ Median nadir CD4 count approximated from weighted average of subgroups.

[^4]: Abbreviations: ARR, adjusted relative risk; ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio; RR, relative risk.

[^5]: ^a^ Median nadir CD4 count approximated from weighted average of subgroups.

[^6]: Abbreviations: SMART, Strategies for Management of Antiretroviral Therapy; START, Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.
